Latin America’s IVD Sector Exceeds USD 2 Billion, Brazil leads
By LabMedica International staff writers Posted on 29 Mar 2015 |
The Latin American in vitro diagnostics (IVD) sector was estimated at USD 2.4 billion in 2014. Population growth, government insurance, newly insured patients, and updated healthcare facilities have driven growth in the region and will continue to propel demand, according to Kalorama Information (New York, NY, USA).
Kalorama based its finding on market research and interviews with IVD manufacturers and distributors. The analysis, published in Kalorama’s report “The Market for In Vitro Diagnostic Tests In Latin America," focuses on reagents and instruments in the main countries. Brazil, Chile, Columbia, Peru and Argentina are singled out for a deeper level of analysis. Uruguay, Venezuela, Ecuador, and other nations are also considered.
“The maturation of IVD markets in developed countries has IVD companies casting their nets in developing countries where rising incomes and standards of living are anticipated to spark a new health consciousness population with growing demands for quality medical care,” said Bruce Carlson, Kalorama Information publisher, “Latin America is a key target for IVD manufacturers,” expected to give additional opportunities in the near future, at an average annual growth twice the worldwide rate.
Brazil has the number one IVD market in the Latin America. The sector is growing at good pace in Brazil, Chile, and Colombia. Due to their current political and economic situations other nations might lag behind for some time. Kalorama’s report suggests this region’s IVD market is attractive but has large challenges to overcome, about which the report provides guidance.
“One of the challenges is that each country is a world on its own: different regulations on sales, insured populations, reimbursement policies, and a number of logistic issues.” said Mr. Carlson, “That’s why we attempted to provide as much detail as possible by country.” Tailored strategies are needed for each of the countries, which vary in size, healthcare infrastructure, and affordability. Companies preparing to enter this market need to understand regulations, have dedicated bilingual personnel, and optimize post-sales costs through regional training centers.
“Marketing strategies from mature markets might end up failing in these countries,” said Mr. Carlson, “working with distributors that fully understand the region is key.” The report provides information on distributors that lead sales in each country, as well as market share tables for each featured country and for many product categories.
Related Links:
Kalorama Information
Market for In Vitro Diagnostic Tests In Latin America, report
Kalorama based its finding on market research and interviews with IVD manufacturers and distributors. The analysis, published in Kalorama’s report “The Market for In Vitro Diagnostic Tests In Latin America," focuses on reagents and instruments in the main countries. Brazil, Chile, Columbia, Peru and Argentina are singled out for a deeper level of analysis. Uruguay, Venezuela, Ecuador, and other nations are also considered.
“The maturation of IVD markets in developed countries has IVD companies casting their nets in developing countries where rising incomes and standards of living are anticipated to spark a new health consciousness population with growing demands for quality medical care,” said Bruce Carlson, Kalorama Information publisher, “Latin America is a key target for IVD manufacturers,” expected to give additional opportunities in the near future, at an average annual growth twice the worldwide rate.
Brazil has the number one IVD market in the Latin America. The sector is growing at good pace in Brazil, Chile, and Colombia. Due to their current political and economic situations other nations might lag behind for some time. Kalorama’s report suggests this region’s IVD market is attractive but has large challenges to overcome, about which the report provides guidance.
“One of the challenges is that each country is a world on its own: different regulations on sales, insured populations, reimbursement policies, and a number of logistic issues.” said Mr. Carlson, “That’s why we attempted to provide as much detail as possible by country.” Tailored strategies are needed for each of the countries, which vary in size, healthcare infrastructure, and affordability. Companies preparing to enter this market need to understand regulations, have dedicated bilingual personnel, and optimize post-sales costs through regional training centers.
“Marketing strategies from mature markets might end up failing in these countries,” said Mr. Carlson, “working with distributors that fully understand the region is key.” The report provides information on distributors that lead sales in each country, as well as market share tables for each featured country and for many product categories.
Related Links:
Kalorama Information
Market for In Vitro Diagnostic Tests In Latin America, report
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance